We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App

Twist Bioscience Launches Synthetic RNA Control for UK Variant Strain of SARS-CoV-2

By LabMedica International staff writers
Posted on 24 Dec 2020
Print article
Twist Bioscience Corporation (San Francisco, CA, USA) has launched a new synthetic RNA control that includes the new variant of SARS-CoV-2 circulating in the UK and South Africa.

This new variant strain of SARS-CoV-2 contains multiple spike protein mutations as well as mutations in other areas of the viral genome. According to the European Centers for Disease Control, preliminary analysis in the UK suggests that this variant is significantly more transmissible than previously circulating variants, with an estimated increased transmissibility of up to 70%. The newly identified strain is known as the B1.1.7 lineage, variant under investigation VUI-202012/01, and does not appear to be more deadly than prior strains of SARS-CoV-2. With this new strain, some of the RT-PCR probes used widely in COVID-19 testing no longer detect the S gene that codes for the spike protein in SARS-CoV-2.
Platinum Supplier
ADAMTS13 Activity Assay
HemosIL ADAMTS13 Activity Assay
Influenza & COVID-19 Test
Influenza & COVID-19 Ag Combo Rapid Test Cassette (Swab)
Visit expo >

In March, Twist had launched synthetic SARS-CoV-2 RNA distinct reference sequences as positive controls for the development of both next-generation sequencing (NGS) and reverse transcription-polymerase chain reaction (RT-PCR) assays to test for SARS-CoV-2. These controls continue to be included in many different assays worldwide and can be used to determine the limit of detection, monitor day-to-day test variations and are included on the US Food and Drug Administration (FDA) website as reference materials for SARS-CoV-2. In June, additional SARS-CoV-2 controls were released to cover the evolution of the virus. The Twist synthetic controls are designed based on specific SARS-CoV-2 variants, cover the full viral genome and are sequence-verified.

“With SARS-CoV-2 moving quickly throughout countries and regions, at Twist we remain vigilant in identifying ways we can support in the fight against the pandemic,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “With sequence data available for this new rapidly spreading strain only recently, we quickly leveraged our synthesis platform to begin the process of offering synthetic controls for this specific mutation so our customers can implement any needed changes in their testing protocols and development objectives. We believe that now more than ever, we must continue to respond rapidly, bringing our expertise and tools to the fore in the fight against COVID-19.”

Related Links:
Twist Bioscience Corporation

Print article


Molecular Diagnostics

view channel
Image: Histopathology of neurofibrillary tangles in the brain of a patient with Alzheimer`s disease (Bielschowski silver stain) (Photo courtesy of Dimitri P. Agamanolis, MD).

Alzheimer's Disease Subtypes Proposed from Brain Gene Expression Profiles

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, estimated to affect more than 5.8 million individuals in the USA and more than 50 million worldwide, with almost half of individuals... Read more


view channel

Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.